Keywords: Shire, USA, Replagal, Velaglucerase, Fabry disease, Gaucher disease, BLA filing

Shire submits Replagal BLA with the USA’s FDA; recaps velaglucerase status

Article | 23 December 2009

Print This

Specialty biopharmaceutical company Shire says that it has submitted a Biologics License Application (BLA) with the USA’s Food and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in